GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (FRA:TRB) » Definitions » Cyclically Adjusted FCF per Share

Trinity Biotech (FRA:TRB) Cyclically Adjusted FCF per Share : €-1.05 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Trinity Biotech Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Trinity Biotech's adjusted free cash flow per share for the three months ended in Dec. 2023 was €-0.047. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.05 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -17.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -37.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Trinity Biotech was 88.40% per year. The lowest was -196.20% per year. And the median was -37.40% per year.

As of today (2024-05-15), Trinity Biotech's current stock price is €2.12. Trinity Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was €-1.05. Trinity Biotech's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Trinity Biotech was 1652.50. The lowest was 43.21. And the median was 134.43.


Trinity Biotech Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Trinity Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Cyclically Adjusted FCF per Share Chart

Trinity Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.47 -0.59 -0.88 -1.22 -1.05

Trinity Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.22 -1.17 -1.23 -1.31 -1.05

Competitive Comparison of Trinity Biotech's Cyclically Adjusted FCF per Share

For the Diagnostics & Research subindustry, Trinity Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Cyclically Adjusted Price-to-FCF falls into.



Trinity Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Trinity Biotech's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.047/120.1096*120.1096
=-0.047

Current CPI (Dec. 2023) = 120.1096.

Trinity Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.636 100.573 -0.760
201406 -0.288 100.773 -0.343
201409 -0.192 100.474 -0.230
201412 -0.574 99.576 -0.692
201503 -0.657 99.975 -0.789
201506 -0.961 100.573 -1.148
201509 -0.110 100.274 -0.132
201512 -0.681 99.676 -0.821
201603 -0.595 99.676 -0.717
201606 -0.769 101.072 -0.914
201609 -0.027 100.274 -0.032
201612 -0.469 99.676 -0.565
201703 -0.773 100.374 -0.925
201706 0.041 100.673 0.049
201709 0.054 100.474 0.065
201712 -0.480 100.075 -0.576
201803 -0.508 100.573 -0.607
201806 0.000 101.072 0.000
201809 -0.225 101.371 -0.267
201812 -0.556 100.773 -0.663
201903 -0.541 101.670 -0.639
201906 -0.293 102.168 -0.344
201909 0.018 102.268 0.021
201912 -0.574 102.068 -0.675
202003 -0.490 102.367 -0.575
202006 -0.034 101.769 -0.040
202009 0.700 101.072 0.832
202012 2.472 101.072 2.938
202103 0.591 102.367 0.693
202106 -0.201 103.364 -0.234
202109 -0.051 104.859 -0.058
202112 0.207 106.653 0.233
202203 -0.593 109.245 -0.652
202206 -0.520 112.734 -0.554
202209 -0.086 113.431 -0.091
202212 0.086 115.425 0.089
202303 -0.410 117.618 -0.419
202306 -0.601 119.611 -0.604
202309 -0.646 120.708 -0.643
202312 -0.047 120.110 -0.047

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Trinity Biotech  (FRA:TRB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Trinity Biotech was 1652.50. The lowest was 43.21. And the median was 134.43.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Trinity Biotech Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (FRA:TRB) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.

Trinity Biotech (FRA:TRB) Headlines

No Headlines